Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir, now marketed as Yeztugo. As of February 25, 2026, the biopharmaceutical giant has successfully transitioned from a provider of daily oral regimens
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total transaction value of up to $2.4 billion. The deal centers on Orna’s proprietary circular RNA (oRNA)
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to be available at veterinary clinics and hospitals nationwide in spring 2026.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg), (MK-8591A)] in adults with HIV-1. The findings were shared in late-breaking presentations at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) being held in Denver.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, Mar. 3, 2026, at 1:50 p.m. EST.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success.
According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire founder, Dr. Patrick Soon-Shiong, the company has rapidly evolved into a commercial-stage powerhouse in the immunotherapy landscape. ImmunityBio is currently in focus due to [...]
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the safety, efficacy and pharmacokinetics of ENFLONSIA™ (clesrovimab) in infants and children at increased risk for severe respiratory syncytial virus (RSV) disease over two RSV seasons. The data were presented during an oral session (Abstract #P455) at RSVVW’26, the 9th conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy.
Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development. The agreement integrates Mayo Clinic's Platform architecture as well as clinical and genomic datasets with Merck's ambition to harness AI-enabled virtual cell technologies to enhance disease understanding, improve target identification and drive early development decisions.
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based biotechnology pioneer is now fighting to prove that its messenger RNA (mRNA) platform is a "one-hit wonder" no more. The company has dominated recent financial [...]
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that could redefine the standard of care in bladder and kidney cancers. With the conference just ten days away, the
Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s expectations. Despite reporting a net loss, the company’s narrower-than-anticipated deficit of $2.11 per share and revenue of $678 million signaled
The Dow Jones Industrial Average endured a chilling session this Friday, February 13, 2026, dropping 267.77 points, or 0.54%, to close at 49,184.21. The slide marked the second consecutive day of losses for the blue-chip index, following a more severe 669-point tumble on Thursday. What began
"Too big to fail" is how we would describe the megacap stocks in this article today.
While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.
The United States merger and acquisition (M&A) landscape has entered a transformative era in early 2026, marking a definitive end to the deal-making drought that plagued the previous two years. Driven by a relentless AI supercycle and a dramatic shift toward "regulatory pragmatism," the market is witnessing what analysts
As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying technology giants, investors have executed a massive "Great Rotation," fleeing overextended tech valuations in favor of the stability and renewed
